Ticker HubNasdaq

AGIO

Agios Pharmaceuticals, Inc.

PHARMACEUTICAL PREPARATIONS

Latest price

$36.85-0.41%

As of Oct 26, 2026, 4:01 PM EDT · Market data by Massive

Market cap

$2.2B

Volume

838.5K

Previous close

$37.00

Day range

$36.63 – $38.13

Listed

Jul 24, 2013

Coverage

1 article

Price performance

Recent trading

5 trading days · 15-minute intervals · ET

Five-day open $35.20Latest interval $36.85

Newsroom

Latest AGIO coverage

CompanyDeep DiveNov 27, 2025

Sickle-Cell Setback Or Acquisition Setup? Agios’ 48% Drop Could Draw Dealmakers

Agios plunged 48% after its Phase III Pyrukynd trial delivered mixed results, missing key pain-crisis and fatigue endpoints. Despite strong hemoglobin gains, AGIO still seeks FDA approval.

AGIO

Company overview

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 540
Headquarters: CAMBRIDGE, MA
CIK: 0001439222

Company website View advanced chart

SEC filings

No filing records are attached to this profile yet.

Browse EDGAR

Profile at a glance

Jul 24, 2013

Listed

540

Employees

Market data may be delayed and is provided for informational purposes only. SmallCapsDaily content is not investment advice.